RE:RE:RE:RE:The PlanHi RPINVESTOR1,
In reference to your comment regarding Andrew's father I am reminded that in the Mainpointe collaboration agreement signed in 2021 the following was agreed upon:
"The agreements signed between RepliCel and MainPointe include a Share Purchase Agreement for the purchase of common shares at a price which is equal to the greater of $0.675 per share or the discounted market price per share (as defined in the policies of the TSX Venture Exchange) for a total investment of CAD $2,700,000 spread over an 8-month period. RepliCel’s shares closed market trading yesterday at CAD $0.20 per share. MainPointe has also agreed to pay the costs related to securing FDA approvals to market launch RepliCel's dermal injector and consumables (the “RepliCel Injector Product Line”) in the United States. " You mention that we have not heard anything regarding the Dermal Injector since the last AGM. Have they purposely stalled the development and FDA Approval of the device while this take-over bid has been formulated ? Was Mainpointe not responsible for all costs in the pursuit of this Approval ?